Skip to main content
Caplight Logo









ViCentra

ViCentra

Private
UtrechtHealthcare & Life Scienceshttps://hellokaleido.com/

Last Round

Series D

Extension

Jan 8, 2026

Total Funding Raised

$207.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ViCentra is a medical device company that develops and manufactures the Kaleido insulin patch pump system, a small and light wearable device designed for people with diabetes.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT

Business Model

B2C

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Application

Keywords

insulin pumppatch pumpwearable medical deviceautomated insulin deliveryAIDdiabetes managementhybrid closed-looprazor and blademedical hardwareinsulin therapyhealth IoTdigital healthCGM integrationmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ViCentra Comparables

Compare ViCentra with similar companies based on industry and business-model similarity.

ViCentra comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MicroTech
81%
EOFlow Co., Ltd.
80%
Terumo Corporation
76%

ViCentra Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionJan 8, 2026
Series DSep 3, 2025
Series CDec 16, 2021
Corporate FundingJun 30, 2020
Series BJan 16, 2016

ViCentra Investors

Notable investors and investment history

ViCentra investors
InvestorRounds
Kreos CapitalCorporate Funding
Venturing TechSeries D, Series D Extension
EQT Life SciencesSeries C, Series D, Corporate Funding, Series B
Invest-NLSeries C, Series D, Corporate Funding
ROM Utrecht RegionSeries D, Series D Extension
Kreos CapitalCorporate Funding
Partners in EquitySeries D, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 4, 2026

    Mediq named as a distribution partner.

  • May 4, 2026

    Kaleido system integrates with Diabeloop's DBLG1/DBLG2 algorithm.

ViCentra Filings

Explore SEC and related filing metadata, where available.

ViCentra filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ViCentra's valuation, stock price, and market status.

Is ViCentra a public or private company?

ViCentra is a private company.

What is the current stock price of ViCentra?

ViCentra is a private company with no public stock price. No recent secondary market data is available.

How much is ViCentra worth (valuation)?

Valuation information for ViCentra is not publicly available.

Can I buy ViCentra stock?

ViCentra shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ViCentra's last funding round?

ViCentra's most recent funding round was Series D Extension on January 8, 2026.

Who are the main investors in ViCentra?

Key investors in ViCentra include EQT Life Sciences, Invest-NL, Partners in Equity, Inkef Capital, Innovation Industries.

Will ViCentra IPO soon?

No public IPO plans have been announced for ViCentra.

How can I track ViCentra secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ViCentra's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersUtrecht
Employee Range159
Year Founded2013
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?